ArticleJCO precision oncology2026

Erratum: Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.

Alessandro Di Federico et al.PubMed ↗Publisher ↗

No numbers read from the abstract.